Axim Biotechnologies IncOTCQB:AXIM
- LAST PRICE0.0150
- TODAY'S CHANGE (%)-0.0005 (-3.2258%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0150 / 0.0155
- Day Range
- 52 Week Range
- Volume172,106
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AXIM |
|---|---|---|
| 09:32 ET | 547 | 0.015 |
| 09:45 ET | 4500 | 0.015 |
| 10:19 ET | 26666 | 0.014 |
| 10:21 ET | 500 | 0.015 |
| 01:53 ET | 38879 | 0.015 |
| 03:00 ET | 100000 | 0.013 |
| 03:09 ET | 100 | 0.01365 |
| 03:12 ET | 900 | 0.015 |
Mar 27, 2024
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024, from 9:01AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:01AM ET on Wednesday Mar 27, 2024 by Dow JonesVIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024, from 9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Axim Biotechnologies Inc | 4.3M | -0.4x | --- |
Psycheceutical Bioscience Inc | 4.3M | -0.1x | --- |
Genprex Inc | 4.2M | -0.1x | --- |
Tharimmune Inc | 4.5M | 0.0x | --- |
Cingulate Inc | 4.4M | 0.0x | --- |
Artelo Biosciences Inc | 4.1M | -0.4x | --- |
Company Information
Axim Biotechnologies, Inc. is an international healthcare diagnostic solutions development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. It has developed and commercialized two highly specialized point-of-care (POC) diagnostic tests, Ocular Immunoglobulin E (IgE) test and Lactoferrin test, which are designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient DED and non-specific allergic conjunctivitis. In addition, it is also engaged in the development of a quantitative tear MMP-9 test to measure the intensity of inflammation affecting dry eye patients. It has also developed proprietary assays for the detection of QSOX1-L in patients undergoing cancer treatment. Its products also include SARS-CoV-2 neutralizing antibody tests and a fentanyl neutralizing antibody test.
Contact Information
- Headquarters
- 6191 Cornerstone Court, E, Suite 114SAN DIEGO, CA, United States 92121
- Phone
- 212-751-0001
- Fax
- 775-786-6755
Executives
- President, Chief Executive Officer, Director
- John Huemoeller
- Chief Financial Officer, Company Secretary
- Robert Malasek
- Chief Executive Officer, Co-Founder of Sapphire Biotech, Inc
- Catalina Valencia
- Chief Operating Officer
- Kurt Phinney
- Chief Medical Officer
- Joseph Tauber
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
|---|---|
Revenue (TTM) | $34.5K |
Shares Outstanding | 278.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-0.03 |
Book Value | $-0.03 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 125.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,602.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
